Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00542646
NCT00542646UnknownEarly Phase 1

Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System

PeriTec Biosciences Ltd.1 site in 1 country45 target enrollmentStarted: November 1, 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Early Phase 1
Sponsor
Enrollment
45
Locations
1
Primary Endpoint
Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The occurrence of Peripheral Vascular Disease has been increasing which includes the large artery in the upper leg called Superficial Femoral Artery (SFA). The Peritoneal Lined Stent has been developed as a new method for treating narrowed area in the SFA. This research study will determine the safety and effectiveness of the Peritoneal Lined Stent in keeping th Superficial Femoral Artery open and allowing blood to flow in the leg.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient with claudication or ischemic rest pain(Rutherford Categories 2-4)
  • •The angiogram will need to have been performed confirming superficial femoral artery short segment occlusion(<5cm first two patients and <10cm there on) or high grade(>50%)stenosis
  • •Patient has a signed and dated informed consent
  • •Patient has a resting ABI <0.9 or an abnormal exercise ABI if resting ABI is normal. Patients with incompressible arteries (ABI >1.2) must have TBI <0.8
  • •Life expectancy greater than one year
  • •The ability to comply with protocol follow up requirements and required testing
  • •Angiographic lesion requirements assessed at time of procedure
  • •Lesion of the superficial femoral artery with a short segment occlusion(<5cm first two patients and <10cm there on) or high grade (>50%) stenosis
  • •Target lesion 1 cm below profunda/superficial femoral artery origin and 3cm above knee joint
  • •Angiographic evidence of a minimum of at least one tibial with continuous artery runoff to the ankle that does not require intervention
  • •Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel, and successful placement of 9 french(Fr) sheath

Exclusion Criteria

  • •Untreated iliac artery in-flow limiting lesion
  • •Significant proximal common femoral or superficial femoral artery disease above or below target lesion
  • •Any previously treated superficial femoral artery lesion
  • •Any previous stenting or surgery in the target vessel
  • •Femoral or popliteal aneurysm
  • •Non-Atherosclerotic disease resulting in occlusion (e.g. embolism, vasculitis,etc)
  • •Serum creatinine >2.5 mg/dl
  • •Any previously known coagulation disorder, including hypercoagulability
  • •Severe medical co-morbidities or other medical condition (for example untreated coronary heart disease and congestive heart failure, severe chronic obstructive pulmonary disease, metastasis malignance, etc.)

Outcomes

Primary Outcomes

Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events

Time Frame: 30 Days

Secondary Outcomes

  • Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization(3 Months Intervals except for Target Lesion Revascularization at 12 months)

Investigators

Sponsor
PeriTec Biosciences Ltd.
Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb IschemiaCritical Limb Ischemia
NCT02260622Ottawa Hospital Research Institute20
Completed
Phase 2
Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent ClaudicationIntermittent ClaudicationPeripheral Arterial Disease
NCT01890135University of Virginia31
Completed
Phase 4
Pilot Study of Vitamin D Screening Use in Peripheral Arterial Disease Patient Over Maximum Distance WalkingPeripheral Arterial Disease
NCT03615833University Hospital, Angers27
Completed
Not Applicable
Optimising the Efficacy, Patient Perception and Uptake of an Exercise Programme in People in Intermittent ClaudicationVascular DiseaseIntermittent Claudication
NCT02641418Hull University Teaching Hospitals NHS Trust109
Completed
Not Applicable
Vastmanland Myocardial Infarction Study (VaMIS)Peripheral Artery DiseaseDiabetesAcute Myocardial Infarction
NCT01452178Uppsala University1,008
Pilot Study to Evaluate the Safety and... | Clinical Trial